NeuroPace Inc
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System. The company designs, manufactures, and sells a brain-responsive neuromodulation platform that monitors electrical activity in the brain and delivers targeted stimulation at the seizure source.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaImplantable brain-responsive neuromodulation devices and related therapy for epilepsy.
Sales tied to replacement of implanted RNS devices at end of service life.
Adjunct epilepsy-related products sold to the existing customer base during wind-down.
Service revenue and collaboration-related services, including work for partners.
Asiakkaat
NeuroPace sells primarily to hospital facilities that implant the RNS System for patients with drug-resistant epilepsy. The key users and influencers are epileptologists, neurosurgeons, and epilepsy centers that evaluate candidates, perform implantation, and manage follow-up care. A smaller portion of activity comes from related product sales to the existing customer base and collaboration services.
Buy RNS Systems for initial implants and replacement procedures for eligible epilepsy patients.
Evaluate, refer, and implant patients; they are the main channel for adoption and utilization.
Epileptologists and neurosurgeons influence prescribing, implantation, and follow-up care.
Patients returning for replacement procedures as devices reach end of service.
Counterparties receiving collaboration services and limited DIXI-related products.
Strategia
NeuroPace is focused on expanding adoption of the RNS System across comprehensive epilepsy centers and broader referral pathways in the United States. Its strategy also includes clinical studies, regulatory work to support indication expansion, and continued development of future neuromodulation products.
Adoption depends on physician awareness, referrals, and center-level penetration.
Broader labels can enlarge the addressable epilepsy population and support long-term growth.
Long-term outcomes and continuous brain data support physician adoption and differentiation.
New products can extend the platform beyond the current epilepsy indication.
Maantiede
Q1/2026NeuroPace is primarily a U.S. business, with nearly all revenue generated in the United States. The company also has limited sales in Canada under a special approval program, and it manufactures and distributes products from its Mountain View, California facility.
Riskit
NeuroPace depends heavily on a single commercial product and a narrow U.S. epilepsy indication, so adoption, reimbursement, and physician preference are central to performance. The company also faces competition from larger neuromodulation manufacturers, regulatory dependence on FDA approvals, and operational exposure tied to manufacturing, cybersecurity, and data privacy.
- Dependence on a single product and indicationVaikutus: KorkeaTodennäköisyys: Kohtalainen
Most revenue comes from the RNS System for adults with drug-resistant focal epilepsy.
Kohdistuu: U.S. epilepsy market
- Competitive pressure from larger device makersVaikutus: KorkeaTodennäköisyys: Kohtalainen
LivaNova and Medtronic have greater scale, resources, and market presence.
Kohdistuu: Neuromodulation therapies
- Regulatory and clinical adoption riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Growth depends on FDA approvals, clinical evidence, and physician acceptance.
Kohdistuu: Indication expansion and new center adoption
- Manufacturing and supply continuityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Devices are manufactured and distributed from a single California facility.
Kohdistuu: Mountain View operations
- Cybersecurity and patient-data privacyVaikutus: KeskitasoTodennäköisyys: Matala
The business handles sensitive health data and relies on connected systems and third parties.
Kohdistuu: Remote monitoring and cloud/IT systems
Kirjanpito
Harkinnanvaraiset erätDevice sales, replacement procedures, and collaboration services may be recognized differently and at different times.
Vaikutus: Affects quarterly revenue comparability and mix analysis
Longer battery life changes the timing of replacement procedures and can shift revenue patterns.
Vaikutus: Can create quarter-to-quarter variability in revenue and gross margin
Management identifies this as a critical estimate for a device business with specialized inventory.
Vaikutus: Can materially affect cost of goods sold and gross profit
Equity awards, offerings, and debt financing influence reported expenses and capital structure.
Vaikutus: Affects operating expense presentation and dilution analysis
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Neuronetics, Inc.
STIM · Surgical & Medical Instruments & Apparatus
Neuraxis, INC
NRXS · Electromedical & Electrotherapeutic Apparatus
Neuraxis, INC is a U.S.-based medical device company focused on neuromodulation therapies for pediatric and adult patients.
Inspire Medical Systems, Inc.
INSP · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea.
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Firefly Neuroscience, Inc
AIFF · Services-Prepackaged Software
Pulse Biosciences, Inc
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
Päivitetty: 24.9.2026